Abstract
The success of coronary artery bypass grafting (CABG) surgery mainly depends on the pa‐ tency of graft vessels. The predominant mechanism of early graft failure after coronary sur‐ gery is associated with antiplatelet treatment using drungs such as acetylsalicylic acid (ASA). Prevention using oral ASA in the early postoperative phase in patients with vascular disease is associated with a 25% to 44% reduction in adverse cardiovascular events (1; 2). Daily ASA doses ranging between 75-1200mg can similarly reduce fatal and nonfatal events (2; 3), although studies directly comparing lower and higher doses with regard to clinical outcomes in the CABG setting have been lacking [4].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
